Primary myelofibrosis (PMF; myelofibrosis, idiopathic myelofibrosis, chronic idiopathic myelofibrosis; incl. post-PV/post-ET MF)
Myeloproliferative neoplasm · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Clonal MPN with marrow fibrosis, extramedullary haematopoiesis and massive splenomegaly. Leukoerythroblastic film with tear-drop cells. Presents with anaemia, constitutional symptoms, abdominal fullness, cytopenias, or thrombosis. ED role: recognise, exclude acute complications (splenic infarct, bleeding, infection, portal hypertension), refer for JAK-inhibitor/transplant assessment.
Red flags
- Splenic infarction (acute left-upper-quadrant pain, pleuritic, rub)
- Bleeding with thrombocytopenia
- Febrile neutropenia / infection on cytopenia
- Blasts on film / rapid count change (transformation to AML)
- Portal hypertension - variceal bleed, ascites
- Bone pain, severe constitutional symptoms (progressive disease)
Assessment
Differential diagnosis
- Other MPN (PV, ET, CML - BCR-ABL)
- Myelodysplastic syndrome / MDS-MPN overlap
- Marrow infiltration (metastatic cancer, lymphoma, myeloma)
- Secondary/reactive myelofibrosis (infection, autoimmune, vitamin deficiency)
- Hairy cell leukaemia (also causes dry tap/splenomegaly)
Investigations
- FBC + blood film (leukoerythroblastic: tear-drop poikilocytes, nucleated RBCs, immature myeloid cells)
- JAK2 V617F, CALR, MPL mutation panel; BCR-ABL1 to exclude CML
- Bone marrow aspirate (often 'dry tap') + trephine showing fibrosis (reticulin/collagen)
- U&E, urate, LDH (raised), LFTs (portal hypertension)
- USS abdomen - splenomegaly, portal flow
- Risk score (DIPSS/DIPSS-plus) for prognosis
Management
- Confirm with film + mutation + marrow; exclude CML and secondary causes
- Treat acute presentations: splenic infarct (analgesia), bleeding, infection (cytopenic sepsis pathway), symptomatic anaemia
- Symptomatic splenomegaly / constitutional symptoms: JAK inhibitor (ruxolitinib) - haematology-directed
- Anaemia management: transfusion support, consider danazol/EPO/thalidomide-steroid per specialist
- Assess transplant eligibility (only curative option) in intermediate-2/high-risk fit patients
- Manage portal hypertension complications; VTE prophylaxis balanced against bleeding/thrombocytopenia
Drugs & doses
Ruxolitinib 15-20 mg PO twice daily (dose by platelet count), reduces spleen size and symptoms [verify local dose]
Transfuse packed red cells for symptomatic anaemia (restrictive threshold)
Hydroxycarbamide for symptomatic thrombocytosis/leucocytosis/splenomegaly [verify local dose]
Danazol / erythropoiesis-stimulating agent for anaemia per specialist [verify local dose]
Allopurinol 100-300 mg PO once daily for hyperuricaemia [verify local dose]
Allogeneic stem cell transplant - only curative therapy (eligible patients)
Disposition
Acute complication (infarct, bleed, sepsis, transformation) -> admit with haematology. Stable new diagnosis -> urgent outpatient haematology for risk scoring and treatment planning.
Complications & pitfalls
- Leukaemic (AML) transformation
- Progressive marrow failure (infection, bleeding, transfusion dependence)
- Portal hypertension / extramedullary haematopoiesis
- Splenic infarction / rupture
- Thrombosis and cachexia
Exam pearls
- Tear-drop cells + leukoerythroblastic film + massive splenomegaly = think myelofibrosis
- 'Dry tap' on marrow aspirate is characteristic - trephine needed for fibrosis
- Ruxolitinib improves symptoms/splenomegaly and survival but is not curative - only allo-transplant is
- DIPSS/DIPSS-plus guides prognosis and transplant timing
- Abrupt ruxolitinib withdrawal can cause a cytokine rebound ('discontinuation syndrome')
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.